URGN Q2 2024 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+3.4% YoY

Gross Profit

$20M89.8% margin

Operating Income

-$26M-118.3% margin

Net Income

-$33M-152.9% margin

EPS (Diluted)

$-0.91

QoQ Revenue Growth

+16.3%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$282M

Total Liabilities

$252M

Stockholders' Equity

$30M

Cash & Equivalents

$220M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$21M	+3.4%
Gross Profit	$20M	$19M	+4.9%
Operating Income	-$26M	-$15M	-68.0%
Net Income	-$33M	-$24M	-38.4%

Revenue Segments

Jelmyto

$22M100%